-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Downgrades Summit Therapeutics to Hold, Lowers Price Target to $15

Benzinga·03/16/2026 12:45:10
Listen to the news
Jefferies analyst Clara Dong downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Hold and lowers the price target from $42 to $15.